Cantourage Group SE Set for Record-Breaking Q1 Sales

Cantourage Group SE is expected to achieve record sales for Q1, with €14.9m in sales over the first two months, outperforming last year's Q1 sales of €6.2m. This projection suggests Q1 sales could reach €22m, despite no significant regulatory changes until April of the previous year. The company's forecast for 2025 anticipates a 67% year-on-year sales growth, aiming for €86m.

To manage rising demand in Germany, the UK, and Poland, Cantourage plans to increase processing capacity, following an expansion less than ten months ago. The company projects a growing EBITDA margin, reaching 10% despite expansion costs.

Despite potential political uncertainties in Germany, Cantourage's focus on the medical cannabis market reduces potential risks. The company’s expansion into new regions further mitigates these risks. Analysts recommend a "Buy" with a target price of €12.50, based on discounted cash flow analysis.